Journal article
Use of antibacterial prophylaxis for patients with neutropenia
MA Slavin, S Lingaratnam, L Mileshkin, DL Booth, MJ Cain, DS Ritchie, A Wei, KA Thursky
Internal Medicine Journal | WILEY-BLACKWELL | Published : 2011
Abstract
The use of oral prophylactic antibiotics in patients with neutropenia is controversial and not recommended by this group because of a lack of evidence showing a reduction in mortality and concerns that such practice promotes antimicrobial resistance. Recent evidence has demonstrated non-significant but consistent, improvement in all-cause mortality when fluoroquinolones (FQs) are used as primary prophylaxis. However, the consensus was that this evidence was not strong enough to recommend prophylaxis. The evidence base for FQ prophylaxis is presented alongside current consensus opinion to guide the appropriate and judicious use of these agents. Due consideration is given to patient risk, as i..
View full abstractGrants
Funding Acknowledgements
[ "Funding: Victorian Integrated Cancer Services, administered by Western and Central Melbourne Integrated Cancer Services.", "Conflict of interest: The following authors are consultants or advisory committee members or receive honoraria, fees for service, or travel assistance (independent of research-related meetings) from; or have research or other associations with the organisations listed: Monica Slavin - Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough; Senthil Lingaratnam - Victorian Integrated Cancer Services; Andrew Wei - Celgene, Hospira, Novartis; Karin Thursky - Gilead, Merck Sharp & Dohme, Pfizer, Schering Plough." ]